Tinzaparin sodium

Tinzaparin sodium
	n = 1 to 25, R = H or SO3Na, R1 = H, SO3Na or COCH3, R2 = H and R3 = COONa or R2 = COONa and R3 = H
Clinical data
Trade names	innohep(R)
AHFS/Drugs.com	Monograph
Routes of; administration	subcutaneous (once daily)
ATC code	B01AB10 (WHO) ;
Legal status
Legal status	US: WARNING;
Pharmacokinetic data
Bioavailability	90% for Anti-Xa activity, 67% for Anti-IIa activity)
Metabolism	minor metabolisation in liver by desulfation and/or depolymerization; excretion via kidneys in almost unchanged form
Elimination half-life	200 min. for Anti-Xa activity, 257. min for Anti-IIa activity
Identifiers
CAS Number	9041-08-1 (sodium salt);
ChemSpider	none;
UNII	3S182ET3UA;
KEGG	D06398 ;
ChEMBL	ChEMBL1201414 ;
ECHA InfoCard	100.110.590
Chemical and physical data
Molar mass	6500 g/mol (average)
	(what is this?) (verify)

Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).^[5]

It can be given subcutaneously by syringe, or intravenously.^[6] It was manufactured by Leo pharmaceutical company, who withdrew the product from the US in 2011 due to low sales and a contamination issue.^[7]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^ Cheer S.M. et al. Drugs 2004; 64 (13): 1479–1502
^ Pedersen P.C. et al. Thromb Res 1991; 61 (5-6): 477-487
^ European Pharmacopoeia, 6th Edition, 2008
^ Hull et al. NEJM 1992;326,15:975-982
^ Farmaceutiska Specialiteter i Sverige - the Swedish official drug catalog. Fass.se Archived 21 January 2011 at the Wayback Machine > Innohep
^ "Drug Shortages List". Archived from the original on 5 October 2016. Retrieved 4 October 2016.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

[2] Cheer S.M. et al. Drugs 2004; 64 (13): 1479–1502

[3] Pedersen P.C. et al. Thromb Res 1991; 61 (5-6): 477-487

[4] European Pharmacopoeia, 6th Edition, 2008

[5] Hull et al. NEJM 1992;326,15:975-982

[6] Farmaceutiska Specialiteter i Sverige - the Swedish official drug catalog. Fass.se Archived 21 January 2011 at the Wayback Machine > Innohep

[7] "Drug Shortages List". Archived from the original on 5 October 2016. Retrieved 4 October 2016.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Clinical data
n = 1 to 25, R = H or SO₃Na, R¹ = H, SO₃Na or COCH₃, R² = H and R³ = COONa or R² = COONa and R³ = H
Trade names	innohep(R)
AHFS/Drugs.com	Monograph
Routes of administration	subcutaneous (once daily)
ATC code	B01AB10 (WHO)
Legal status
Legal status	US: WARNING^[1]
Pharmacokinetic data
Bioavailability	90% for Anti-Xa activity, 67% for Anti-IIa activity)^[2]
Metabolism	minor metabolisation in liver by desulfation and/or depolymerization; excretion via kidneys in almost unchanged form
Elimination half-life	200 min. for Anti-Xa activity, 257. min for Anti-IIa activity ^[3]
Identifiers
CAS Number	9041-08-1^N (sodium salt)
ChemSpider	none
UNII	3S182ET3UA
KEGG	D06398^Y
ChEMBL	ChEMBL1201414^N
ECHA InfoCard	100.110.590
Chemical and physical data
Molar mass	6500 g/mol (average)^[4]
^NY (what is this?) (verify)